<DOC>
	<DOCNO>NCT01301443</DOCNO>
	<brief_summary>The purpose first man study examine safety experimental gene transfer agent , RetinoStat , design treat neovascular age-related macular degeneration .</brief_summary>
	<brief_title>Phase I Dose Escalation Safety Study RetinoStat Advanced Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>There two part study . A dose-escalation phase look three dos RetinoStat start low dose , three patient recruit dose level . The escalation phase follow dose confirmation phase high dose safe well tolerate examine 9 patient .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Clinical diagnosis AMD active CNV show evidence leakage . BCVA le equal 20/200 study eye dose escalation phase . BCVA le equal 20/80 study eye maximum tolerate dose phase . Significant ocular abnormality prevent retinal assessment . Treatment steroid within three month screen . Treatment antiVEGF therapy either eye within one month screening . Clinically significant intercurrent illness , laboratory , ECG chest XRay abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Age Related Macular Degeneration</keyword>
</DOC>